A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets

Vaccine

Volumn 32, Issue 35, 2014, Pages 4571-4577

  Wong, Sook San ^a   Jeevan, Trushar ^a   Kercher, Lisa ^a   Yoon, Sun Woo ^a,b   Petkova, Atanaska Marinova ^a   Crumpton, Jeri Carol ^a   Franks, John ^a   Debeauchamp, Jennifer ^a   Rubrum, Adam ^a   Seiler, Patrick ^a   Krauss, Scott ^a   Webster, Robert ^a   Webby, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Ferrets; H7N9; Vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; FERRET; HEMAGGLUTINATION INHIBITION TEST; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TITRIMETRY; VIRUS LOAD; WILD TYPE; ANIMAL; BLOOD; IMMUNOLOGY; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VIROLOGY; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; SEVERITY OF ILLNESS INDEX; VACCINES, INACTIVATED; VIRAL LOAD; VIRUS SHEDDING;

EID: 84904393681     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.016     Document Type: Article

References (39)

1. World Health Organization, Number of confirmed human cases of avian influenza A (H7N9) reported to WHO, 〈http://www.who.int/influenza/human_animal_interface/influenza_h7n9/10u_ReportWebH7N9Number.pdf〉 (last accessed: 1/21/2014).
2. Gao H.N., Lu H.Z., Cao B., Du B., Shang H., Gan J.H., et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368:2277-2285.
3. Hu Y., Lu S., Song Z., Wang W., Hao P., Li J., et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013, 381:2273-2279.
4. Yen H.L., McKimm-Breschkin J.L., Choy K.T., Wong D.D., Cheung P.P., Zhou J., et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio 2013, 4.
5. Lam T.T., Wang J., Shen Y., Zhou B., Duan L., Cheung C.L., et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013, 502:241-244.
6. World Health Organization, Vaccine response to the avian influenza A(H7N9) outbreak, 〈http://www.who.int/influenza/vaccines/virus/CandidateVaccineVirusesH7N9_02May13〉 (last accessed: 10/14/2013).
7. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
8. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
9. Reber A.J., Chirkova T., Kim J.H., Cao W., Biber R., Shay D.K., et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis 2012, 3:68-90.
10. Gross P.A., Ennis F.A., Gaerlan P.F., Denson L.J., Denning C.R., Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977, 136:623-632.
11. Wright P.F., Dolin R., La Montagne J.R. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration summary of clinical trials of influenza vaccines-II. J Infect Dis 1976, 134:633-638.
12. Couch R.B., Decker W.K., Utama B., Atmar R.L., Nino D., Feng J.Q., et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza A H5, H7 and H9 vaccines in humans. PLoS One 2012, 7:e50830.
13. Couch R.B., Patel S.M., Wade-Bowers C.L., Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012, 7:e49704.
14. De Groot A.S., Ardito M., Terry F., Levitz L., Ross T., Moise L., et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccines Immunother 2013, 9:950-956.
15. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363:1099-1103.
16. World Health Organization, WHO provisional recommendation on influenza A(H7N9) vaccine virus, 〈http://www.who.int/influenza/human_animal_interface/influenza_h7n9/ProvisionalRecommendation_H7N9_31May13.pdf〉 (last accessed: 1/21/2014).
17. World Health Organization, Summary of status of development and availability of avian influenza A (H7N9) candidate vaccine viruses, 〈http://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_h7n9_cvv_20130712.pdf〉 (last accessed: 10/15/2013).
18. Liu M., Wood J.M., Ellis T., Krauss S., Seiler P., Johnson C., et al. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 2003, 314:580-590.
19. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol 1938, 27:493-497.
20. Network WHOGIS Serological diagnosis of influenza by hemagglutination inhibition testing. Manual for the laboratory diagnosis and virological surveillance of influenza 2011, 59-62. WHO Press, Geneva.
21. European Agency for the Evaluation of Medicinal Product, Note for guidance on harmonisation of requirements for influenza vaccines, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf〉 (last accessed: 1/21/2014).
22. Wood J.M., Levandowski R.A. The influenza vaccine licensing process. Vaccine 2003, 21:1786-1788.
23. Lipatov A.S., Hoffmann E., Salomon R., Yen H.L., Webster R.G. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006, 194:1040-1043.
24. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Nat Acad Sci USA 2005, 102:12915-12920.
25. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63:1239-1246.
26. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4:e59.
27. Smith G.E., Flyer D.C., Raghunandan R., Liu Y., Wei Z., Wu Y., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31:4305-4313.
28. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
29. Lopez-Martinez I., Balish A., Barrera-Badillo G., Jones J., Nunez-Garcia T.E., Jang Y., et al. Highly pathogenic avian influenza A (H7N3) virus in poultry workers, Mexico, 2012. Emerg Infect Dis 2013, 2013.
30. Cox R.J., Madhun A.S., Hauge S., Sjursen H., Major D., Kuhne M., et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27:1889-1897.
31. Talaat K.R., Karron R.A., Callahan K.A., Luke C.J., DiLorenzo S.C., Chen G.L., et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
32. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009, 199:711-716.
33. Talaat K.R., Karron R.A., Luke C.J., Thumar B., McMahon B.A., Chen G.L., et al. An open label phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011, 29:3144-3148.
34. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
35. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
36. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3:e1401.
37. Das S.C., Hatta M., Wilker P.R., Myc A., Hamouda T., Neumann G., et al. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012, 30:6871-6877.
38. Hamouda T., Sutcliffe J.A., Ciotti S., Baker J.R. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin Vaccine Immunol: CVI 2011, 18:1167-1175.
39. Maltais A.K., Stittelaar K.J., Kroeze E.J., van Amerongen G., Dijkshoorn M.L., Krestin G.P., et al. Intranasally administered endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Vaccine 2014, 32:3307-3315.